Published online before print August 7, 2003, doi: 10.1161/01.STR.0000088062.86084.F2
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2003;34:2165.)
© 2003 American Heart Association, Inc.
Original Contributions |
Profiles of Matrix Metalloproteinases, Their Inhibitors, and Laminin in Stroke Patients
Influence of Different Therapies
From the Department of Neurology, Medical School, University of Heidelberg, Heidelberg, Germany (S.H., P.K., S.W.); Division of Biostatistics, Scripps Research Institute, La Jolla, Calif (J.K.); and Biogen, Cambridge, Mass (H.G.)
Correspondence to Simone Wagner, MD, Department of Neurology, University of Heidelberg, INF 400, 69120 Heidelberg, Germany. E-mail simone_wagner{at}med.uni-heidelberg.de
Background and Purpose— The goal of this study was to determine the temporal profile of several matrix metalloproteinases (MMPs), tissue inhibitors of MMPs (TIMPs), and laminin (an MMP substrate) in human stroke under different treatment paradigms, including thrombolysis and hypothermia.
Methods— We serially measured the serum levels of MMP-2, MMP-3, MMP-9, MMP-13, TIMP-1, TIMP-2, and laminin in 50 patients with acute ischemic stroke using zymography or enzyme-linked immunosorbent assay. Patients were treated with heparin, therapeutic thrombolysis, or hypothermia. Scandinavian Stroke Scale scores were obtained at baseline. Infarct volume was measured with CT scanning on day 4 after stroke onset. Healthy persons were used as control subjects.
Results— MMP-2 and MMP-9 increased during the course of ischemia, whereas intact laminin and TIMP-2 decreased significantly (P<0.05). MMP-9 and laminin levels varied significantly by infarct size (P=0.001) and therapy (P=0.0005). MMP-9 levels were significantly higher in patients treated with tissue plasminogen activator (tPA) compared with patients treated with hypothermia. The cleaved form of MMP-9 was found solely in 4 patients treated with tPA. Intact laminin levels were significantly lower in the tPA group than in the hypothermia group.
Conclusions— Selected MMPs and TIMPs are involved in the pathophysiology of acute stroke. This is also reflected by changes in laminin. Treatment paradigms differentially influence levels of MMP-9 and laminin. Combination therapies explicitly involving MMP inhibition could be of value in future treatment strategies.
Key Words: hypothermia • metalloproteinases • stroke, ischemic • thrombolytic therapy
This article has been cited by other articles:
 |
|
 |
|
  K. Jeyaseelan, K. Y. Lim, and A. Armugam MicroRNA Expression in the Blood and Brain of Rats Subjected to Transient Focal Ischemia by Middle Cerebral Artery Occlusion Stroke, March 1, 2008; 39(3): 959 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nakaji, M. Ihara, C. Takahashi, S. Itohara, M. Noda, R. Takahashi, and H. Tomimoto Matrix Metalloproteinase-2 Plays a Critical Role in the Pathogenesis of White Matter Lesions After Chronic Cerebral Hypoperfusion in Rodents Stroke, November 1, 2006; 37(11): 2816 - 2823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ning, K. L. Furie, W. J. Koroshetz, H. Lee, M. Barron, M. Lederer, X. Wang, M. Zhu, A. G. Sorensen, E. H. Lo, et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke Neurology, May 23, 2006; 66(10): 1550 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tsuji, T. Aoki, E. Tejima, K. Arai, S.-R. Lee, D. N. Atochin, P. L. Huang, X. Wang, J. Montaner, and E. H. Lo Tissue Plasminogen Activator Promotes Matrix Metalloproteinase-9 Upregulation After Focal Cerebral Ischemia Stroke, September 1, 2005; 36(9): 1954 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Gu, J. Cui, S. Brown, R. Fridman, S. Mobashery, A. Y. Strongin, and S. A. Lipton A Highly Specific Inhibitor of Matrix Metalloproteinase-9 Rescues Laminin from Proteolysis and Neurons from Apoptosis in Transient Focal Cerebral Ischemia J. Neurosci., July 6, 2005; 25(27): 6401 - 6408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rosell, J. Alvarez-Sabin, J. F. Arenillas, A. Rovira, P. Delgado, I. Fernandez-Cadenas, A. Penalba, C. A. Molina, and J. Montaner A Matrix Metalloproteinase Protein Array Reveals a Strong Relation Between MMP-9 and MMP-13 With Diffusion-Weighted Image Lesion Increase in Human Stroke Stroke, July 1, 2005; 36(7): 1415 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Kauppinen and R. A. Swanson Poly(ADP-Ribose) Polymerase-1 Promotes Microglial Activation, Proliferation, and Matrix Metalloproteinase-9-Mediated Neuron Death J. Immunol., February 15, 2005; 174(4): 2288 - 2296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Silva, R. Leira, J. Tejada, J. M. Lainez, J. Castillo, A. Davalos, and by the Stroke Project, Cerebrovascular Diseases Gr Molecular Signatures of Vascular Injury Are Associated With Early Growth of Intracerebral Hemorrhage Stroke, January 1, 2005; 36(1): 86 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, K. Tsuji, S.-R. Lee, M. Ning, K. L. Furie, A. M. Buchan, and E. H. Lo Mechanisms of Hemorrhagic Transformation After Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke Stroke, November 1, 2004; 35(11_suppl_1): 2726 - 2730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Lo, J. P. Broderick, and M. A. Moskowitz tPA and Proteolysis in the Neurovascular Unit Stroke, February 1, 2004; 35(2): 354 - 356. [Full Text] [PDF]
|
|
|
|
|
|
J. Montaner Editorial Comment--Cooling Matrix Metalloproteinases to Improve Thrombolysis in Acute Ischemic Stroke Stroke, September 1, 2003; 34(9): 2171 - 2172. [Full Text] [PDF]
|
|